Fontan circulation is associated with an increased risk of thromboembolism [1] [2] [3] and the prevalence of thromboembolic events has been reported to range from 3% to 30% among Fontan patients. [4] [5] [6] [7] [8] Various abnormalities in the coagulation system have been postulated as the mechanism of the increased incidence of thromboembolism in Fontan patients, including decreased levels of protein C, protein S, and antithrombin III. 1, 9, 10 Although platelets play an important role in thrombus formation, and collagen-induced and adenosine-induced platelet aggregation are elevated in patients after the Fontan procedure, 11 whether platelets are indeed activated after the Fontan procedure remains unknown. P-selectin is an adhesion molecule found in the secretory granules of platelets, and is mobilized to the membrane surface on activation. [12] [13] [14] [15] [16] [17] [18] Activated platelets expressing P-selectin on the surface release their granule contents, which facilitates the adhesion of platelets and neutrophils to the endothelium and causes platelet aggregation and thrombus enlargement by recruitment of leucocytes and platelets. 19 Thus P-selectin expressed on platelets is likely to play an important role in thrombus formation. Measurement of P-selectin expression on the platelet surface is a very sensitive method of determining platelet activation. 12, [20] [21] [22] However, there have not been any studies evaluating platelet P-selectin in Fontan patients.
Because platelets are activated under conditions of endothelial dysfunction, 23, 24 in the current study, we measured plasma thrombomodulin (TM) levels as a marker of endothelial function. TM is expressed mainly on the surface of vascular endothelial cells, it suppresses blood coagulation, and is a key component of the protein C anticoagulant pathway. TM converts thrombin from a procoagulant to an anticoagulant protease by increasing the rate of protein C activation. 25 We also measured protein C activity level as a marker of the anticoagulant pathway and the plasma thrombin-antithrombin complex III (TAT) level was measured to evaluate coagulability. on aspirin, ticlopidine, warfarin or a combination with heparin.
Four patients in the present study developed thrombus and all had been on warfarin (Table 1) . Thrombus was observed in the right atrium in patients 40, 41 and 42, and in the left atrium in patient 43 at the time of the blood test.
As disease controls, we also studied 23 patients with congenital heart disease who had undergone biventricular repair using 2 ventricles (14 men, 9 women; mean age 21± 9 years, range 5-35). The diagnosis was congenital aortic valve stenosis in 1 patient, atrioventricular septal defect in 3 patients, coarctation of the aorta in 1 patient, congenitally corrected transposition of the great arteries in 2 patients, double-outlet right ventricle in 4 patients, coronary aneurysm in 1 patient, annuloaortic ectasia in Marfan syndrome in 2 patients, pulmonary atresia with intact ventricular septum in 1 patient, a single left ventricle in 1 patient, a common arterial trunk in 1 patient, tetralogy of Fallot in 4 patients, and ventricular septal defect in 2 patients.
Twelve healthy subjects without cardiopulmonary disease (5 men, 7 women; mean age 24±5 years, range 18-33 years) served as healthy controls. All subjects gave informed consent for the present study. 
Methods
We tested blood samples taken from the patients while they were in a stable condition. None of the patients had undergone cardiac surgery or cardiac catheterization within 1 month of sampling. Whole blood was obtained from an antecubital vein without venous stasis using a 22-gauge needle. The first 3 drops of blood were discarded before the collection of blood used for analysis. The blood was mixed with 0.38% trisodium citrate. Immediately after the collection of the blood, we evaluated the expression of P-selectin on platelets as follows. Samples were analyzed on a FACS caliber flow cytometer with Cell Quest software (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). A gate was set around the platelets, and 10,000 were counted from each sample. The platelets were incubated with fluorescein isothiocyanate-conjugated anti-P-selectin monoclonal antibody (AK4, mouse IgG1, Becton Dickinson) at room temperature for 30 min, and then fixed in 1% (vol/vol) paraformaldehyde and analyzed using flow cytometry. Platelet P-selectin was expressed as mean fluorescence intensity (MFI). We measured plasma TM level, protein C activity, and TAT level using standard clinical laboratory methods. When the values of platelet P-selectin, plasma TM, protein C activity and/or TAT were markedly abnormal, we re-evaluated the data 1 week later to confirm that the data were indeed abnormal (data not shown).
Statistical Analysis
Data are expressed as the mean ± standard deviation of the mean. Data of the Fontan patients, healthy controls, and disease controls were compared using the Mann-Whitney U test. Comparison of thromboembolic factors between the 2 types of Fontan procedure was by Student's t-test. Spearman's correlation coefficient by rank was used to evaluate the expression of P-selectin, TM and the interval after the Fontan operation. A level of P<0.05 was considered significant.
Results
The expression of P-selectin on platelets was significantly greater in the Fontan patients (4.5±1.4 MFI) than in the healthy controls (3.4±0.4; P<0.001) or the disease controls (3.7±0.8; P<0.05) ( Figure 1A ). Plasma TM levels were significantly lower in the Fontan patients (1.5±0.8) than in the healthy (2.2±0.3) and disease controls (1.9±0.5) ( Figure 1B ). Protein C activity was lower in the Fontan patients than in healthy controls (71±35 vs 118±25%; P<0.001) ( Figure 1C) . TAT levels were greater in the Fontan patients than in the healthy controls (80.2±322.6 vs 1.9±0.9 ng/ml; P<0.05) ( Figure 1D ).
Many Fontan patients showed elevated P-selectin expression on platelets, and only 1 of 4 patients who developed thrombus had elevated P-selectin expression on platelets and elevated TAT levels (Table 1) . In all 4 patients who developed thrombus, however, plasma TM levels and protein C activity were low. Because the postoperative interval was longer in patients who developed thrombus, the relationships between P-selectin and plasma TM levels and the interval after the Fontan procedure were evaluated ( Figure 2 ). Although there was no correlation between P-selectin expression and the interval after the Fontan procedure, there was a negative correlation between TM level and the postoperative interval (P<0.05, r=-0.3). In patients after APC, the platelet P-selectin was higher (P<0.05) and the plasma TM level (P<0.05) lower than in patients after TCPC. In patients after TCPC, protein C activity was lower than that in patients after APC (P<0.01) ( Table 2 ). In addition, these thromboembolic factors were independent of the brain natriuretic peptide (BNP) values (Table 1) .
Discussion Platelet P-Selectin
The present study has demonstrated, for the first time, that P-selectin expression on platelets is elevated in patients after the Fontan procedure, indicating that platelet activation does occur in these patients. This characteristic of the Fontan patients was not observed in the disease controls who had undergone biventricular repair using 2 ventricles. We previously reported that increased expression of platelet P-selectin was a risk factor for thromboembolism in patients with cyanotic congenital heart disease. 26 After the Fontan procedure, patients do not have cyanosis but still have a high risk of thromboembolism. Elevated P-selectin level has also been reported in patients with congestive heart failure, [27] [28] [29] atrial fibrillation, 12 non-valvular atrial fibrillation after ischemic stroke, 30 and primary pulmonary hypertension. 18 Platelet activation under these conditions may be related to the increased shear stress and/or endothelial dysfunction. 23 Interestingly, many patients were receiving an antiplatelet drug (aspirin or ticlopidine) or a combination of an antiplatelet and an anticoagulant drug (heparin or warfarin), and their platelet P-selectin levels were still elevated. Chung et al demonstrated a significant reduction in the platelet P-selectin level following treatment of acute heart failure. 28 In the present study, there was no correlation between platelet P-selectin level and hemodynamic data (central venous pressure, diameter of the inferior vena cava, and BNP values) ( Table 1 ; data for central venous pressure and diameter of the inferior vena cava are not shown). The effect of antiplatelet drugs on platelet P-selectin levels remains unclear. It is also unknown whether anticoagulation/antiplatelet therapy should be administered routinely to all Fontan patients.
Endothelial Dysfunction and Coagulability in Fontan Patients
TM facilitates the activation of protein C by thrombin. 25, [31] [32] [33] [34] [35] Thrombin bound to TM cannot convert fibrinogen to fibrin or activate protein C. Activated protein C is known to inhibit clotting factors V and VIII. [32] [33] [34] [35] Therefore, TM acts as an intrinsic anticoagulant barrier between the blood and the endothelium, 25, 36 playing a pivotal role in maintaining the coagulation balance. In our study, the findings of lower plasma TM levels and protein C activity suggest impaired endothelial function in Fontan patients ( Figures 1B, C) . Previous studies using near-infrared spectroscopy and flowmediated vasodilatation have suggested that endothelial function in Fontan patients is impaired. 37, 38 The endothelium in Fontan patients may be fatally damaged by the increased shear stress on the vessel wall caused by increased blood viscosity and/or by chronic hypoxemia before the Fontan procedure. 26, 39 Postoperative Interval After the Fontan Procedure Although plasma TM levels and protein C activity were low in all patients who developed thrombus, only 1 of 4 patients demonstrated elevated P-selectin expression on platelets or elevated TAT level (Figure 1 ). The precise mechanisms by which thrombus is formed in patients after the Fontan procedure remain undetermined, but the process is most likely multifactorial. The elevated TAT levels detected in the present study suggest the presence of coagulation abnormalities after the Fontan procedure, which is in agreement with the findings of previous studies. 1, 9, 10 Thrombosis in the Fontan procedure is often silent and it is not clear exactly when the thrombus forms. Nevertheless, the probability of freedom from thromboembolism decreases with the interval after the Fontan procedure. 3, 4 There was no correlation between P-selectin levels and the postoperative interval in the present study, but we speculate that platelets are activated irrespective of the time interval after the procedure. The negative correlation between TM level and the interval after the Fontan procedure suggests deterioration of endothelial function over time following this surgery ( Figure 2B ), which may partly explain the high prevalence of thromboembolic events long after the Fontan procedure.
Type of Fontan Procedure
Various types of Fontan procedure have evolved over the past 30 years, but the incidence of thromboembolic events in each type has not been defined. In this study, we showed that in patients after APC platelet P-selectin levels were higher and plasma TM levels lower than in patients after TCPC, although in patients after TCPC, protein C activity was lower than that in patients after APC. The condition of low TM level and activated platelet P-selectin is highly prevalent in patients after APC. TCPC, which is a newer technique, may have an advantage over APC in terms of thrombus formation. The long-term results of thromboembolism after TCPC remain to be studied.
Study Limitations
There are limitations in the present study.
(1) The study population was heterogeneous with respect to age, anticoagulation therapy, and cardiac diagnosis. (2) A relatively small number of patients experienced episodes of thromboembolic events and patients with elevated P-selectin expression on the platelets did not necessarily develop episodes of thromboembolic events. (3) The true incidence of cardiac thrombus may have been underestimated, because transesophageal echocardiography was not performed on a routine basis in all of the patients. (4) We could not obtain set time interval data, because the patients' visits to the hospital were determined by their condition. (5) We could not determine which type of Fontan procedure was recommended, because modified TCPC was performed later in the study. Nevertheless, the present study results show that platelet activation and endothelial dysfunction occurs in Fontan patients. In future studies, we need to further examine the relationship between platelet activation and thrombus formation using more accurate modalities such as contrast computed tomography and/or transesophageal echocardiography on a routine basis.
In conclusion, platelet P-selectin and plasma TAT levels were elevated, whereas TM levels and protein C activation were decreased in Fontan patients. These abnormalities may be potential risk factors for thromboembolic events. Thrombogenicity still continues despite the finding that cyanosis is settled by the Fontan procedure.
